a
a
Weather:
No weather information available
HomeHealthXYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

Key points: Wearable AF monitoring devices are extensively used in routine practice worldwide. The FDA has agreed on the use of AF monitoring devices in clinical trials for budiodarone approval. The FDA has also issued guidance on the steps required to incorporate wearable AF monitoring…

No comments

Sorry, the comment form is closed at this time.

Translate »